10x Genomics Inc (NASDAQ:TXG) price on current trading day, fall -4.75% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $15.23.
A look at the stock’s price movement, the close in the last trading session was $15.99, moving within a range at $15.1 and $16.06. The beta value (5-Year monthly) was 1.873. Turning to its 52-week performance, $57.90 and $12.95 were the 52-week high and 52-week low respectively. Overall, TXG moved -12.17% over the past month.
10x Genomics Inc’s market cap currently stands at around $1.84 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 153.46M for the company’s revenue for the quarter, with a low and high estimate of 151.49M and 155.1M respectively. The average forecast suggests down to a -16.59% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 599.35M, representing a -3.13% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TXG is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 5 analyst(s) rate the stock as a Hold, 3 recommend TXG as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TXG’s current price about 2.00% and -7.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 47.49, while 7-day volatility ratio is 5.10% and 5.85% in the 30-day chart. Further, 10x Genomics Inc (TXG) has a beta value of 1.82, and an average true range (ATR) of 0.91. Analysts have given the company’s stock an average 52-week price target of $28.5, forecast between a low of $24 and high of $46. Looking at the price targets, the low is -57.58% off current price level while to achieve the yearly target high, price needs to move -202.04%. Nonetheless, investors will most likely welcome a -87.13% jump to $28.5 which is the analysts’ median price.
If we refocus on 10x Genomics Inc (NASDAQ:TXG), historical trading data shows that trading volumes averaged 2.06 over the past 10 days and 1.99 million over the past 3 months. The company’s latest data on shares outstanding shows there are 106.98 million shares.
The 17.60% of 10x Genomics Inc’s shares are in the hands of company insiders while institutional holders own 78.78% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.86 million on 2024-11-15, giving us a short ratio of 3.39. The data shows that as of 2024-11-15 short interest in 10x Genomics Inc (TXG) stood at 742.00004 of shares outstanding, with shares short falling to 7.65 million registered in 2024-10-15. Current price change has pushed the stock -72.78% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TXG stock continues to rise going into the next quarter.
